Stocks of Chinese pharmaceutical companies posted the worst drop in almost a decade after the drug prices in the government procurement tumbled, sparking concerns that in the future companies will have to make sharp price cut to win government order.
Preliminary results for the tender on Thursday shows that prices on drugs that made into a government procurement list were cut substantially. In particular, the price for one hepatitis B . . .
To continue reading, please subscribe.
We highly value independence. Yuan Talks is solely funded by subscriptions from thousands of intelligent readers like you. Don't miss out!
What you'll get:
- Original and in-depth reporting on China's economy and financial markets with details, data and perspectives you don't read elsewhere!
- Daily Brief newsletter delivered before market open every weekday wrapping up the most important China-related information.
- Weekly Market Wrap-up on Chinese equities, bonds, the yuan and commodities!
- Interviews with China experts. We find you insights you should never miss!
Not ready for the full service? Subscribe to our Free Weekly Newsletter first.
Already have an account? Sign In